Literature DB >> 2517106

Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus.

G M Pacifici1, M Franchi, L Giuliani, A Rane.   

Abstract

The activity of the microsomal glucuronyltransferase (GT) was measured in 34 fetal and 27 adult human livers with 2-naphthol as substrate. The average (+/- SD) enzyme activity was 0.07 +/- 0.07 nmol/min/mg protein (fetal) and 7.98 +/- 4.19 nmol/min/mg protein (adult) livers. The adult to fetal ratio of the GT activity was 114. The activity of the cytosolic sulphotransferase (ST) was measured with 2-naphthol as substrate in 30 fetal and 23 adult livers. ST activity (mean +/- SD) was 0.18 +/- 0.12 nmol/min/mg protein (fetal) and 0.63 +/- 0.22 nmol/min/mg protein (adult). The adult to fetal ratio of the ST activity was 3.5. The postnatal development of GT is more marked than that of ST. In the fetal livers, the rate of 2-naphthol sulfation correlated (p less than 0.01) with the rate of 2-naphthol glucuronidation, whereas they did not correlate in the adult livers. No relationship was observed between the activity of the GT or ST and gestational age. The correlation existing between ST and GT in human fetus might suggest that the two enzymes are under a common developmental pattern which seems to be independent of gestational age. The activity of the GT with morphine as substrate was measured in 25 fetal and 29 adult livers and found to be 0.23 +/- 0.20 nmol/min/mg protein (fetal) and 1.85 +/- 0.98 nmol/min/mg protein (adult). Thus, the adult to fetal ratio of morphine glucuronidation was 8.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2517106

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  20 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Uridine 5'-diphosphoglucuronic acid (UDPGLcUA) in the human fetal liver, kidney and placenta.

Authors:  M Cappiello; L Giuliani; A Rane; G M Pacifici
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

Review 3.  Population clinical pharmacology of children: modelling covariate effects.

Authors:  Brian J Anderson; Karel Allegaert; Nicholas H G Holford
Journal:  Eur J Pediatr       Date:  2006-06-29       Impact factor: 3.183

Review 4.  Fetal drug metabolism and its possible clinical implications.

Authors:  B Krauer; P Dayer
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

5.  Genetic variation, expression and ontogeny of sulfotransferase SULT2A1 in humans.

Authors:  L Ekström; A Rane
Journal:  Pharmacogenomics J       Date:  2015-03-24       Impact factor: 3.550

Review 6.  Updated perspectives on the cytosolic sulfotransferases (SULTs) and SULT-mediated sulfation.

Authors:  Masahito Suiko; Katsuhisa Kurogi; Takuyu Hashiguchi; Yoichi Sakakibara; Ming-Cheh Liu
Journal:  Biosci Biotechnol Biochem       Date:  2016-09-21       Impact factor: 2.043

7.  Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Authors:  C P Strassburg; A Strassburg; S Kneip; A Barut; R H Tukey; B Rodeck; M P Manns
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

8.  Sulphation and glucuronidation of ritodrine in human foetal and adult tissues.

Authors:  G M Pacifici; M Kubrich; L Giuliani; M de Vries; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial.

Authors:  K J S Anand; B J Anderson; N H G Holford; R W Hall; T Young; B Shephard; N S Desai; B A Barton
Journal:  Br J Anaesth       Date:  2008-08-23       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.